Recent Analysts’ Ratings Changes for Medline (MDLN)

Several brokerages have updated their recommendations and price targets on shares of Medline (NASDAQ: MDLN) in the last few weeks:

• 8/12/2026 – Medline had its price target lowered by JPMorgan Chase & Co. from $53.00 to $46.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – Medline had its price target lowered by Tigress Financial from $62.00 to $55.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Medline had its price target lowered by Wells Fargo & Company from $45.00 to $34.00. They now have an “equal weight” rating on the stock.
• 8/10/2026 – Medline had its price target lowered by TD Cowen from $53.00 to $45.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Medline was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 8/6/2026 – Medline was given a new $42.00 price target by Robert W. Baird.
• 8/6/2026 – Medline was given a new $39.00 price target by Evercore Inc.
• 8/6/2026 – Medline had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $47.00 price target on the stock.
• 8/6/2026 – Medline had its price target lowered by Royal Bank Of Canada from $53.00 to $46.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Medline was given a new $37.00 price target by Deutsche Bank Aktiengesellschaft.
• 8/6/2026 – Medline had its price target lowered by Truist Financial Corporation from $56.00 to $47.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Medline had its price target lowered by Stifel Nicolaus from $50.00 to $45.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Medline was upgraded by Citigroup Inc. to “strong-buy”.
• 7/31/2026 – Medline had its “buy” rating reaffirmed by BTIG Research. They now have a $55.00 price target on the stock.
• 7/23/2026 – Medline was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.

Insiders Place Their Bets

In other Medline news, insider Jessi L. Corcoran acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average cost of $34.15 per share, for a total transaction of $170,750.00. Following the transaction, the insider owned 5,000 shares of the company’s stock, valued at $170,750. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Private Ltd Gic sold 100,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $35.80, for a total value of $3,580,000.00. Following the sale, the insider directly owned 22,802,482 shares of the company’s stock, valued at approximately $816,328,855.60. The trade was a 0.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 4,538,896 shares of company stock worth $161,936,454 over the last ninety days. 0.81% of the stock is currently owned by corporate insiders.

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.